Common diabetes drugs tested to stop mouth lesions from becoming cancer
NCT ID NCT05727761
Summary
This study is testing whether a combination of two existing diabetes medications (pioglitazone and metformin) can shrink or eliminate high-risk white or red patches in the mouth (oral leukoplakia). These patches can sometimes develop into oral cancer. The goal is to see if a 12-week course of these pills can reduce the size and severity of these lesions in participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL LEUKOPLAKIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HealthPartners
RECRUITINGSaint Paul, Minnesota, 55130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.